Gastric Cancer

Circulating tumor DNA detected after resection of stage II colon cancer appears to identify patients who are at high-risk of tumor recurrence.

Here we review the evidence supporting current approaches to resectable gastric cancer, including discussion of the optimal extent of surgery and lymphadenectomy, adjuvant chemotherapy, postoperative chemotherapy with chemoradiation, and perioperative chemotherapy.

Current methods of treatment still have a small impact on the survival of patients with localized disease. Improved understanding of the underlying mutations seen in gastric cancer might suggest alternative treatments and ways to better select patients.

Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.

Lymph node status after undergoing neoadjuvant chemotherapy and resection of esophagogastric cancer was the only independent predictor of survival.

A novel first-in-class antibody can significantly extend median survival when added to standard chemotherapy for patients with advanced gastric cancer.

Combined therapy with trastuzumab and the tyrosine kinase inhibitor lapatinib shows promise against chemotherapy-refractory, HER2-positive colorectal cancers that do not harbor KRAS mutations.

A 35-year-old woman was found to have a 4 cm nodule in the liver. After a biopsy is performed, what is your diagnosis?

For the first time, researchers suggest that underlying genetic mutations may cause pancreatic adenocarcinoma tumors to stiffen up and produce a dangerous thickening and scarring of the tissue around them.

Clinicians now have a new tool to better identify colorectal cancer in its early and more treatable state.

Researchers at Wake Forest Baptist Medical Center’s Institute for Regenerative Medicine are hoping to help advance the war against cancer with a new system called, “metastasis-on-a-chip.”

A 53-year-old man presents with a large hepatic mass. After further evaluation, a biopsy is performed. What is your diagnosis?

A meta-analysis found that a number of dietary factors play a role in the risk of developing gastric cancer, with protective effects seen with fruit and certain vegetables and increased risk seen with high-salt foods and certain forms of alcohol.

Treatment with the PARP inhibitor olaparib plus paclitaxel resulted in an overall survival benefit in patients with metastatic gastric cancer.

New data suggests that an experimental targeted therapy known as IMMU-130 may be effective in controlling drug-resistant metastatic colorectal cancer (mCRC) in patients previously treated with irinotecan-containing chemotherapy regimens.

A 59-year-old man with metastatic gastric cancer presented to the oncology clinic with a 1-week history of positional headache, nausea, and vomiting. He stated that the headache was located in the frontal region, was 8 on a scale of 10 in intensity.

According to a large study, men with a CDH1 gene mutation have a 70% incidence of gastric cancer by the age of 80 years and women have a 56% incidence.

Adding radiotherapy to adjuvant chemotherapy in the ARTIST trial yielded similar results to chemo alone in patients with D2 lymph node-resected gastric cancer.

The FDA approved ramucirumab (Cyramza) in combination with paclitaxel for treating patients with advanced gastric or gastroesophageal junction adenocarcinoma.

In 2008, 770,000 out of 989,000 gastric cancer cases worldwide were attributed to H pylori, suggesting eradication could yield drastic reductions in incidence.

Expression of the protein ALDH1A1 is associated with outcomes in gastric cancer, according to a new study, and could be used as a prognostic tool.

In a preliminary study using a mouse model, researchers found that vagal denervation using Botox or other methods could help slow gastric cancer’s growth.

A new study from The Cancer Genome Atlas proposes a new classification of gastric cancers into four genomic subtypes that could eventually yield better treatment paradigms.

Searching for and eradicating the bacteria Helicobacter pylori could reduce the incidence of gastric cancer in otherwise healthy individuals, especially in Asian populations, according to a new study.

Both esophageal cancer and stomach cancer are aggressive malignancies with contrasting risk factors, histologies, and molecular characteristics-yet for the most part comparable therapeutic approaches.

The purpose of this review is to update, present some of the new data on, and outline the controversies regarding neoadjuvant and adjuvant therapy of esophagogastric junction and gastric adenocarcinoma.

Adding ramucirumab to FOLFOX did not delay progression in patients with untreated advanced gastric or esophageal adenocarcinoma, according to trial results presented at the 2014 ASCO Annual Meeting.

The VEGFR-2 tyrosine kinase inhibitor apatinib significantly prolonged overall survival in patients with advanced gastric cancer compared with placebo, according to the results of a phase III study.

The FDA has approved the angiogenesis inhibitor ramucirumab for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.